While AR-targeted therapies provide a survival benefit for most men, prostate tumours inevitably develop mechanisms of resistance and progress to a lethal disease state termed castration-resistant prostate cancer (CRPC) [[12], [13], [14]]. Here, AR is linked to prostate neoplasm.